Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2020 · 10-Q
Revenue$7.58M$7.58M+45.6% vs Q1 2019 Net Income-$2.20M-$2.20MN/M vs Q1 2019 EPS Diluted-$0.15-$0.15— vs Q1 2019 Gross Profit$4,342,839+19.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow-$3,738,826N/M Free Cash Flowderived-$3,754,763N/M Margins · derivedGross margin57.3%−12.3 pt vs Q1 2019
Operating margin-29.8%−32.3 pt vs Q1 2019
Net margin-29.1%−29.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 6, 2020 · 36 d after period end